Extended Data Fig. 5: Expected increase in survival times. | Nature Medicine

Extended Data Fig. 5: Expected increase in survival times.

From: Screening for idiopathic pulmonary fibrosis using comorbidity signatures in electronic health records

Extended Data Fig. 5

a, Survival function lower bounds at two specificity levels (90 and 95%). b, Cumulative hazard function upper bounds. 95% confidence bounds around the mean shown for both, generated using the Truven dataset (n=2,053,277). c, Variation of the mean survival time as a function of the specificity at which ZCoR-IPF is operated. d, Variation of estimated raw risk as a function of age for screening four years from actual recorded diagnosis of IPF, showing that risk increases almost linearly with age for the patients eventually diagnosed with IPF. e, Degradation of out-of-sample AUC as we attempt to screen earlier, stepping back from the time of current diagnosis (in absence of ZCoR-IPF screening).

Back to article page